Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMC

Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans

Rasouli N., Yao-Borengasser A., Varma V., Spencer HJ., McGehee RE., Peterson CA.

Randomized Controlled Trial on Type 2 Diabetes, published in Arterioscler Thromb Vasc Biol (2009) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Arterioscler Thromb Vasc Biol (2009)
Reported sample size
—
Source database
Europe PMC
PMID
19667111
PMCID
PMC2755066
DOI
10.1161/atvbaha.109.186957
Citations
50

Abstract (original English)

Objective Scavenger receptors play crucial roles in the pathogenesis of atherosclerosis, but their role in insulin resistance has not been explored. We hypothesized that scavenger receptors are present in human adipose tissue resident macrophages, and their gene expression is regulated by adiponectin and thaizolidinediones. Methods and results The gene expression of scavenger receptors including scavenger receptor-A (SRA), CD36, and lectin-like oxidized LDL receptor-1 (LOX-1) were studied in subcutaneous adipose tissue of nondiabetic subjects and in vitro. Adipose tissue SRA expression was independently associated with insulin resistance. Pioglitazone downregulated SRA gene expression in adipose tissue of subjects with impaired glucose tolerance and decreased LOX-1 mRNA in vitro. Macrophage LOX-1 expression was decreased when macrophages were cocultured with adipocytes or when exposed to adipocyte conditioned medium. Adding adiponectin neutralizing antibody resulted in a 2-fold increase in LOX-1 gene expression demonstrating that adiponectin regulates LOX-1 expression. Conclusions Adipose tissue scavenger receptors are strongly associated with insulin resistance. Pioglitazone and adiponectin regulate gene expression of SRA and LOX-1, and this may have clinical implications in arresting the untoward sequalae of insulin resistance and diabetes, including accelerated atheroscleros

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Cell LineAdipocytesMacrophagesHumansInsulin ResistanceObesityMetforminThiazolidinedionesRNA, MessengerHypoglycemic Agents

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research